Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of COVIDITY Vaccine in Healthy Adults
NCT05047445Phase 1Unknown
- Sponsor
- Scancell
- Start
- Oct 2021
- Primary completion
- Dec 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of COVIDITY in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Scancell. Primary endpoints: Safety and tolerability of COVIDITY as assessed by the recording of adverse events (AEs), Safety and tolerability of COVIDITY as assessed by the recording of vital signs and 8 more. Status: unknown.
02
Drugs
COVIDITY
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05047445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05047445.